The GRIK5 antibody is a crucial tool for studying the glutamate receptor ionotropic kainate type subunit 5 (GRIK5), also known as GluK5. which is a key component of kainate receptors—a subclass of ionotropic glutamate receptors (iGluRs). These receptors mediate excitatory neurotransmission in the central nervous system. GRIK5. encoded by the GRIK5 gene, forms heteromeric complexes with other kainate receptor subunits (e.g., GluK1-4) to regulate neuronal excitability, synaptic plasticity, and signal transduction. Unlike AMPA and NMDA receptors, kainate receptors, including those containing GRIK5. modulate both presynaptic neurotransmitter release and postsynaptic responses, influencing cognitive functions, learning, and memory.
GRIK5 antibodies are widely used in research to detect and localize the GRIK5 protein in tissues or cell lines via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Dysregulation of GRIK5 has been implicated in neurological and psychiatric disorders, such as Alzheimer's disease, epilepsy, and schizophrenia, as well as certain cancers. Studies using GRIK5 antibodies have revealed its role in synaptic pathology, neuronal hyperexcitability, and disease mechanisms, making it a potential therapeutic target. These antibodies also aid in exploring GRIK5's expression patterns, post-translational modifications, and interactions with other proteins, advancing our understanding of glutamate signaling in health and disease.